Monday, October 26, 2026 · Daily editionET --:--:--

Finished

Hemopatch to Prevent Lymphatic Leak After Robotic Prostatectomy and Pelvic Lymph Node Dissection

NCT04185922 · Chinese University of Hong Kong · Updated 27 June 2022

What is being tested
Hemopatch
For
Prostate Cancer
Kind of study
Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
Who can join
Ages 18 years and older. About 32 people. The full rules are on the registry page.
Where
Hong Kong
When
Starts or started 27 Feb 2020, ends 10 June 2022. Registered 4 Dec 2019.
Results
None posted yet.

In the researchers' words

Robotic prostatectomy (RARP) is a surgery for treatment localized prostate cancer. Bilateral pelvic lymph node dissection (BPLND) will also be performed if there is an estimated risk of occult nodal metastases exceeding 5%. BPLND in general is a well-tolerated procedure. Lymphatic leak is one of the possible complications after lymph node dissection (BPLND). Lymphocele is a collection of lymphatic fluid after operation. Hemopatch is a material used during operation that may prevent lymphorrhoea. This is a randomizedcontrolled trial that aims at investigating the application of Hemopatch to raw lymphatic tissue in preventing lymphorrhoea. Patients would be divided into 2 groups: with or without the use of Hemopatch during operation. They will be followed up on day 30 to monitor the course of recovery and any complications.
ClinicalTrials.gov, NCT04185922

Sites

  • Prince of Wales HospitalHong Kong, Hong Kong